Asia Pacific T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

The Asia Pacific T cell therapy market was valued at US$ 251.99 million in 2022 and is expected to reach US$ 882.72 million by 2030; it is estimated to grow at a CAGR of 17.0% from 2022 to 2030.

Increasing Number of T-Cell Therapy Approvals Fuels the Asia Pacific T Cell Therapy Market

Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approvals. For instance, in 2023: Janssen's CAR-T cell therapy CARVYKTI (Ciltacabtagene Autoleucel) has been approved as a fourth-line treatment for multiple myeloma patients by the Therapeutic Goods Administration, Australia.

In 2023: The Chinese National Medical Products Administration has approved the use of Fucaso (equecabtagene autoleucel) by Innovent Biologics and IASO Biotechnology (IASO Bio) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). In June 2023, the agency approved the therapy's new drug application (NDA).

In 2023: The first humanized CD19-targeted Chimeric Antigen Receptor T cell (CAR-T cell) therapy product, NexCAR19 (Actalycabtagene autoleucel), has been approved by the Central Drugs Standard Control Organization (CDSO) for use in cases of relapsed/refractory B-cell lymphomas and leukemia in India. Immuno Adoptive Cell Therapy is incubated at IIT Bombay.

In 2023: Yikaida (axicabtagene ciloleucel), an autologous CAR T-cell therapy developed by Fosun Kite Biotechnology, was granted approval by China's National Medical Products Administration (NMPA) for use as a second-line treatment for patients with large B-cell lymphoma.

In 2020: The Ministry of Health, Labor and Welfare (MHLW) of Japan has granted the Foundation for Biomedical Research and Innovation at Kobe ("FBRI") a marketing license to produce and distribute Kymriah (tisagenlecleucel) for patients in Japan. Novartis made this announcement today. With this clearance, FBRI is now the only authorized commercial manufacturing facility in Asia for CAR-T cell therapy.

Thus, the increasing number of approvals for T-cell therapy is fueling the market growth.

Asia Pacific T Cell Therapy Market Overview

The Asia Pacific T-cell therapy market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market in Asia Pacific is expected to witness significant growth as CAR T-cell therapy is efficient in treating cancer, elevating the market growth in the region. Many clinical trials for CAR T-cell therapy are ongoing in the region, offering new opportunities in APAC. China is the largest country in the world for CAR T-cell clinical trials, which hospitals conduct. The CAR-T industry chain is being formed in China, including ongoing and expected regulatory reforms to benefit access to such novel therapies. China approved its first CAR T-cell therapy, relmacabtagene autoleucel of JW Therapeutics, in September 2021 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy.

Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

Asia Pacific T Cell Therapy Market Segmentation

The Asia Pacific T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the Asia Pacific T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the Asia Pacific T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the Asia Pacific T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the Asia Pacific T cell therapy market is segmented into China, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific T cell therapy market in 2022.

Bristol-Myers Squibb Co, Gilead Sciences Inc, Innovent Biologics Inc, Janssen Global Services LLC, JW (Cayman) Therapeutics Co Ltd, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Asia Pacific T cell therapy market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific T cell therapy market
• Highlights key in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific T cell therapy market , thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.